Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

This post was originally published on here VILLEJUIF, France, October 07, 2026–Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026.